In Respiratory tract infection Respiratory tract infections are those infections that can affect the sinuses, throat, airways or lungs. Resporidex 250 mg/4 mg Capsule contains two different medicines, Cefalexin and Bromhexine, that work together to kill the bacteria that cause respiratory tract infections. Cefalexin works by stopping the growth of bacteria. Bromhexine helps to loosen thick mucus, making it easier to cough out. This makes it easier for air to move in and out. It also enhances the activity of Cefalexin against bacteria. It usually makes you feel better within a few days, but you should continue taking it as prescribed even when you feel better to make sure that all bacteria are killed and do not become resistant.
Resporidex 250 mg/4 mg Capsule may cause excessive drowsiness with alcohol.
Resporidex 250 mg/4 mg Capsule is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.
Information regarding the use of Resporidex 250 mg/4 mg Capsule during breastfeeding is not available. Please consult your doctor.
Resporidex 250 mg/4 mg Capsule may cause side effects which could affect your ability to drive.
Resporidex 250 mg/4 mg Capsule should be used with caution in patients with severe kidney disease. Dose adjustment of Resporidex 250 mg/4 mg Capsule may be needed. Please consult your doctor. Limited information is available on the use of Resporidex 250 mg/4 mg Capsule in patients with kidney disease.
Resporidex 250 mg/4 mg Capsule should be used with caution in patients with liver disease. Dose adjustment of Resporidex 250 mg/4 mg Capsule may be needed. Please consult your doctor.
If you miss a dose of Resporidex 250 mg/4 mg Capsule, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Eli Lilly and Company India Pvt Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Zephyr Medicare Pvt Ltd || ₹14.5/tablet (25% cheaper)